FDA Committee Votes 6-6 on Durect’s Non-Opioid Pain DrugAdvisory Panels, Anesthetic and Analgesic Drug Products Advisory Committee, Clinical Data, Clinical Trials, FDA, FDA/Regulatory, Non-opioid painkillers, Postsurgical Pain, R&DThe U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) generated an evenly split vote on whether to recommend approval of Durect Corporation’s Posimir. Read more January 17, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Posimir-FDA-Panel-Vote_BioSpace_1-17-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-01-17 11:00:042020-01-17 11:52:56FDA Committee Votes 6-6 on Durect’s Non-Opioid Pain Drug